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Abstract Chronic, multi-factorial conditions caused by a
complex interaction between genetic and environmental risk
factors frequently share common disease mechanisms, as
evidenced by an overlap between genetic risk factors for
cardiovascular disease (CVD) and Alzheimer’s disease (AD).
Single nucleotide polymorphisms (SNPs) in several genes
including ApoE, MTHFR, HFE and FTO are known to in-
crease the risk of both conditions. The E4 allele of the ApoE
polymorphism is the most extensively studied risk factor for
AD and increases the risk of coronary heart disease by approx-
imately 40%. It furthermore displays differential therapeutic
responses with use of cholesterol-lowering statins and acetyl-
cholinesterase inhibitors, which may also be due to variation in
the CYP2D6 gene in some patients. Disease expression may
be triggered by gene-environment interaction causing conver-
sion of minor metabolic abnormalities into major brain disease
due to cumulative risk. A growing body of evidence supports
the assessment and treatment of CVD risk factors in midlife as
a preventable cause of cognitive decline, morbidity and mor-
tality in old age. In this review, the concept of pathology
supported genetic testing (PSGT) for CVD is described in this
context. PSGTcombines DNA testing with biochemical meas-
urements to determine gene expression and to monitor re-
sponse to treatment. The aim is to diagnose treatable disease
subtypes of complex disorders, facilitate prevention of
cumulative risk and formulate intervention strategies guided
from the genetic background. CVD provides a model to ad-
dress the lifestyle link in most chronic diseases with a genetic
component. Similar preventative measures would apply for
optimisation of heart and brain health.
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Introduction
The rapidly aging population drives an increase in the
incidence and prevalence of cardiovascular disease (CVD),
which in turn contributes to an explosion of vascular de-
mentia (VaD) and Alzheimer’s disease (AD). Many vascular
risk factors such as atherosclerosis, stroke and cardiac dis-
ease could result in cerebrovascular dysfunction and trigger
AD pathology (Rocchi et al. 2009). Many patients with VaD
have clinical features of AD coupled with vascular risk
factors and associated strokes. The overlap between AD
and cerebrovascular disease therefore produces a disorder
that may be amenable to therapeutic approaches based on
either mechanism (Kotze et al. 2006). Research efforts are
increasingly focused on elucidation of the underlying cause
of AD, which has resulted in significant progress in under-
standing the wide range of both genetic and environmental
risk factors that converge into the development and progres-
sion of this common neurodegenerative disease.
Prospective follow-up studies performed in nearly 10 000
Californians over a period of 27 years have shown that the
same risk factors that lead to the development of CVD in
middle age also significantly increase the risk of dementia in
old age (Whitmer et al. 2005a,b). Overweight individuals
had a 35% increased risk, while obesity was associated with
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a 74% increased risk of dementia compared with normal-
weight individuals. High serum cholesterol levels, hyperten-
sion, diabetes and smoking between the ages of 40–44 years
were associated with a 20–40% increased risk of dementia
in old age. Treatment of hypertension was shown to reduce
the risk of dementia by 50% (Poon 2008) and represents one
of several CVD risk factors that can be targeted to protect
against cognitive decline. Matsuzaki et al. (2011) investi-
gated whether abnormal lipid metabolism was associated
with AD pathology (neuritic plaques and neurofibrillary
tangles), and found higher lipid measurements, including
cholesterol and triglycerides, in subjects with neuritic pla-
ques. However, there was no relationship of lipid profile
parameters with neurofibrillary tangles.
Metabolism and the brain
There is a close link between metabolic processes and brain
function. Excessive intake of dietary carbohydrates and
particularly high fructose corn syrup, may lead to oxidative
damage and ultimately apoptosis of brain cells (Seneff et al.
2011). These findings are in accordance with loss of lipid
asymmetry and consequent neurotoxicity as demonstrated in
the AD brain using a mouse model (Bader Lange et al.
2010). Phosphatidyldserine asymmetry was significantly
altered in an age-dependent manner as a result of oxidative
stress and/or apoptosis. The same disease mechanism may
apply to other neurodegenerative diseases that share many
properties with AD.
In an effort to define dietary patterns that promote cog-
nitive health, Bowman et al. (2012) examined the cross-
sectional relationships between nutrient status and psycho-
metric and imaging indices of brain health in 104 dementia-
free elders. Distinct nutrient biomarker patterns analysed in
plasma were shown to account for a significant degree of
variance in both cognitive function and brain volume. More
favourable cognitive and MRI measures were significantly
associated with two nutrient biomarker patterns: one high in
plasma vitamins B (B1, B2, B6, folate and B12), C, D and
E, and another high in plasma marine omega-3 fatty acids. A
high trans fat pattern was consistently associated with worse
cognitive performance and less total cerebral brain volume.
Trans fats may replace docosahexaenoic acid (DHA) in
neuronal membranes and high intake increases the risk of
CVD, systemic inflammation, and endothelial dysfunction
that could explain the deleterious effect on cognitive decline
(Lopez-Garcia et al. 2005; Schaefer et al. 2006; Mozaffarian
et al. 2006). Depression attenuated the relationship between
the omega-3 fatty acids and white matter hyperintensity
volume (Bowman et al. 2012) and should be addressed as
part of a comprehensive CVD and AD risk reduction
strategy.
A diet protective against CVD and AD includes reduced
intake of animal products, especially red and organ meats
and high-fat dairy and avoidance of trans fats, and high
intake of fish, fruit, dark and green leafy vegetables and
cruciferous vegetables (Morris et al. 2004; Scarmeas et al.
2006; Barberger-Gateau et al. 2007; Gu et al. 2010).
However, large clinical trials failed to show the benefit of
vitamin E, B vitamins or DHA (Aisen et al. 2008; Bowman
et al. 2012) despite several previous studies in favour of the
important role of certain nutrients in the prevention of AD.
Given the differences in dietary patterns between popula-
tions, and the interactive nature of nutrient action and me-
tabolism, contradictory findings are not surprising.
Individual genetic differences in the absorption and utilisa-
tion of nutrients in the diet could also affect the risk of
disease development and progression. This underscores the
rationale for an integrative genomic healthcare approach
that collectively incorporates the influence of multiple ge-
netic and environmental risk factors in relation to protective
nutrients in a new integrative medical model for optimising
vascular and brain health.
In this review the genetic link between CVD and AD is
discussed in relation to single nucleotide polymorphisms
(SNPs) in the Apo E, MTHFR, HFE and FTO genes impli-
cated in both conditions. These genes are involved in the
metabolism of fat and cholesterol, folate and homocysteine,
and iron dysregulation in the liver that is closely related to
glucose secretion. We provide the rationale for use of a
pathology supported genetic testing (PSGT) approach to-
wards healthy aging. The aim is to 1) diagnose treatable
genetic subtypes of complex diseases as early as possible, 2)
facilitate the prevention of cumulative risk and 3) formulate
intervention strategies tailored to the needs of the individual.
PSGT is applied with use of the Gknowmix Database
(https//:www.gknowmix.com) that matches known genetic
and environmental risk factors identified in patients with
their medical history and biochemical measurements, allow-
ing for gene expression and response to treatment to be
determined and monitored as part of routine clinical care.
Cholesterol metabolism
Although serum and brain cholesterol are two separate pools
(Bjorkhem 2006) high serum total cholesterol in midlife is
associated with an increased risk of both AD and VaD
(Solomon et al. 2009). Based on the finding that even
moderately elevated cholesterol increases the risk of demen-
tia, these authors recommended early intervention before
underlying disease(s) or symptoms appear.
Prior to the development and implementation of a treat-
ment plan in patients with high cholesterol levels, the extent
to which genetic risk factors may play a role needs to be
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determined. An accurate diagnosis is a prerequisite for op-
timal treatment and the appropriateness of genetic testing
should only be considered after careful documentation of
other potential risk factors. These include a family history of
hypercholesterolaemia and CVD, personal medical history
and current health status, as well as environmental risk
factors such as smoking and body mass index (BMI) known
to influence cholesterol levels. Distinction of patients with
familial hypercholesterolaemia (FH) from those with less
severe forms of dyslipidaemia is very important in the South
African population, where the prevalence of this lipid dis-
order is increased 5–10 times compared to most other pop-
ulations due to a founder effect (Kotze et al. 2003). While
nutrition and lifestyle modifications are sufficient to normal-
ise cholesterol levels in most hypercholesterolaemics, FH
patients additionally require long-term drug treatment to
reduce the risk of premature heart attacks.
Lessons learned from extensive study of FH in the genet-
ically distinct populations of South Africa have led to a
modified approach to risk management of CVD, which cul-
minated in the PSGT approach. Nearly 20 years ago we
demonstrated for the first time that the same FH mutation
could be associated with variable clinical expression, ranging
from occurrence of a myocardial infarction at an early age
(<50 years) to good health into advanced age (>80 years)
in the same family, depending on gene-gene and gene-
environment interaction (Kotze et al. 1993a). The type or
severity of the gene defect furthermore affects serum choles-
terol levels differentially, although not sufficiently to explain
clinical variability in coronary events (Kotze et al. 1993b).
Based on the knowledge that high-risk environments and
modifier genes affecting disease expression in monogenic
conditions such as FH would also increase the risk of CVD
in the general population, a comprehensive CVD multi-gene
test performed in conjunction with a medical and lifestyle
assessment was developed (Kotze et al. 2003; Kotze and
Thiart 2003). This CVD testing approach summarised in
Table 1 can be applied in patients at risk of both CVD and
AD (Kotze et al. 2006). The mutations or functional poly-
morphisms included in the CVD assay was based on their
phenotypic effect, allele frequencies in the local population
and availability of appropriate intervention or treatment
options. The genotypes being tested (i) affect the function or
level (expression) of the gene products, (ii) affect biological
processes involved in CVD and related disorders, and (iii)
have apparent metabolic/clinical implications, either alone or
in combination with other genetic or environmental risk
factors.
FH test The first test option in Table 1 includes eight muta-
tions in the low-density lipoprotein receptor (LDLR) gene
(D154N, Del197, D200G, D206E, C356Y, G361V, V408M,
P664L) (Kotze et al. 2003). Thesemutations account for FH in
the majority of affected patients in the high-risk Afrikaner,
Indian and Ashkenazi-Jewish populations of South Africa.
Less than 10% of FH patients in South Africa have been
correctly diagnosed, despite extensive awareness and publi-
cising of hypercholesterolaemia as a CVD risk factor (Marais
Table 1 Different test options for cardiovascular risk management, indications for referral and clinical applications
Test optionsa Indication of referral Application
FH test FH diagnosis—High pre-treatment total (TC) and
LDL-cholesterol levels in the presence of a strong
family history of early-onset (<55 years) coronary heart
disease and/or xanthomas (TC usually >7.5 mmol/l
with normal triglyceride levels)
Population-specific—Diagnose FH or confirm
clinical diagnosis of FH in the index case.
A positive test enables family screening for
pre-clinical diagnosis in at-risk family members
CVD multi-gene test CVD risk reduction—Normal or abnormal lipid profile,
typically moderate-high pre-treatment serum cholesterol
levels, low HDL-cholesterol and/or high triglycerides.
Elevated Lp(a), hs-CRP, homocysteine, glucose, ferritin
and/or transferrin saturation levels. Medical conditions
associated with increased CVD risk (e.g. obesity,
hypertension, type II diabetes, non-alcoholic fatty liver disease)
Global application—Determine genetic
contributors to disease development/severity
and/or genetic basis of metabolic impairments
and treatment response for risk management
of CVD and related conditions affected by
overlapping genes (e.g. metabolic syndrome,
dementia, thrombophilia, depression and
pregnancy complications)
FH & CVD tests Diagnosis and risk management—Same as above with
elevated pre-treatment serum cholesterol levels
(TC >6 mmol/l). A strong family history of early-onset
(<55 years) coronary heart disease and/or xanthomas
Same as above, with focus on distinguishing
FH from other forms of dyslipidaemia.
Alternatively, to identify additional risk
factors in FH patients aimed at the prevention
of a cumulative effect that may lead to the
development or progression of CVD
FH familial hypercholesterolaemia; CVD cardiovascular disease; Lp(a) Lipoprotein (a); hs-CRP high-sensitivity C-reactive protein.
a In addition to the use of genetic markers abnormalities reported or detected in relevant biochemical parameters are highlighted and taken into
account during interpretation of the genetic results.
Metab Brain Dis (2012) 27:255–266 257
et al. 2004). Vergotine et al. (2001) have demonstrated that
determination of total cholesterol levels in FH families with
known mutations fails to provide the correct diagnosis in
nearly 30% of individuals when the 95th percentile for age
and gender is used, and in 12% of cases when the 80th
percentile is used. Of the 60–70% of South Africans with
high cholesterol levels, 5–10% will have FH. This distinction
is very important for treatment considerations to identify those
at highest risk, as male FH patients have a more than 50% risk
of coronary heart disease by age 50 years and in females the
risk is approximately 30% by age 60. In the high-risk South
African population the average age of death is 45 years in men
with FH (Marais et al. 2004).
CVD multi-gene test The second test option, performed in
conjunction with a medical and lifestyle assessment, includes
multiple mutations of relatively low expression in different
CVD-related genes. In addition to the dyslipidaemia-related
mutations included in the CVD multi-gene assay, genetic
variations involved in folate metabolism (methylation), hae-
mostasis (blood clotting) and iron overload are also assessed
(Kotze et al. 2003; Kotze and Thiart 2003). These include
functional SNPs in the ApoE, (rs429358 and rs7412),
MTHFR (rs1801133 and rs1801131), F2 (rs1799963), FV
(rs6025) and HFE (rs1800562 and rs1799945) genes. The
genetic test results are integrated with clinical indicators of
CVD risk (Table 1) and lifestyle factors to identify a combi-
nation of risk factors that could cause or contribute to disease
development, if left untreated.
Since a prospective genotype-phenotype correlation study
has not been performed to date to illustrate the direct correla-
tion between different levels of the specific combination of
biochemical parameters and the conditions listed in Table 1,
continuous monitoring of health outcomes by participating
clinicians are encouraged using a combined service and re-
search approach. This strategy is in line with the view of
Artinian et al. (2010) who recommended careful examination
of the effectiveness of the intervention strategy in routine
clinical practice, as opposed to efficacy trails that examine
interventions under more structured ideal conditions. The
2020 Goals of the American Heart Association include a
new concept of cardiovascular health that incorporates life-
style risk factors considered key drivers of disease in geneti-
cally predisposed individuals. A multi-disciplinary risk
reduction approach is necessary since all the risk factors that
may lead to complex diseases such as CVD have not yet been
elucidated.
The clinical usefulness of this PSGT approach was
assessed as part of a nutrition intervention study in South
African patients with the metabolic syndrome (MetS) (van
Velden et al. 2007). Use of the multi-gene CVD assay in
these patients could partly explain differential responses to
nutrition intervention because of their genetic background.
Genetic testing revealed that two of the twelve MetS
patients included in this pilot study had FH, while four
individuals tested positive for the cholesterol-raising E4
allele of the apolipoprotein E (ApoE) gene. The ApoE
polymorphism occurs in 30–40% across ethnic groups and
is associated with abnormal lipid levels, as also confirmed in
the general South African population (Kotze et al. 1993b).
The deleterious effects of the ApoE polymorphism are
mediated by modifiable environmental risk factors such as
smoking, diabetes and obesity, which increase the risk of both
CVD and AD (Whitmer et al. 2005a, b). While FH patients
require long-term drug treatment with cholesterol-lowering
statins, diet and lifestyle modification is the treatment method
of choice in hypercholesterolaemics with the Apo E4 allele.
The PSGT approach combines genetic testing with blood
biochemistry (pathology) tests to determine gene expression
and to monitor the effectiveness of the treatment strategy
advised. Identification of a genetic risk factor in the pres-
ence of high cholesterol levels would confirm a genetic
contribution to the risk profile, and in some patients a
treatable genetic subtype such as FH or type III dysbetali-
poproteinaemia may be diagnosed after taking all known
risk factors documented into account. When a cholesterol-
raising genetic risk factor is identified in the presence of
normal cholesterol levels it does not mean that the individ-
ual has a disease or will develop CVD, but that a genetic
predisposition was identified that may in future turn into
disease if a high-risk environment is entered. High choles-
terol levels or CVD in the absence of any of the genetic risk
factors tested for may furthermore point to lifestyle risk
factors such as smoking or obesity as the main causative
factors, if present. These clinical features may also be
caused by the inheritance of other genetic risk factors not
included in the initial genetic analysis. Based on the family
history and health status of the individual extended mutation
analysis may be recommended in some patients, as part of
the diagnostic work-up towards development of a pathology
supported gene-based risk reduction plan. According to
Artinian et al. (2010) a programme of counselling with
extended follow-up performed in conjunction with self-
monitoring and goal-setting provides the best approach to
sustainable lifestyle changes to improve clinical outcome.
Our PSGT approach requires regular monitoring (e.g. 6-
monthly) of blood biochemistry levels, where appropriate,
to assess the effectiveness of the intervention strategy.
In addition to its role in lipid metabolism, variation in the
ApoE gene is also associated with inflammation and oxida-
tive stress. This may explain why smoking exacerbates the
deleterious effect of the ApoE E4 allele on arterial wall
thickening (Humphries et al. 2001). ApoE E4 was shown
to be more susceptible to oxidation than the E2 and E3
isoforms and in mice, atherosclerosis could be reversed by
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dietary vitamin E supplementation (Pratico et al. 1998). To
achieve healthy aging, life-long low dietary fat intake
appears to be especially important in individuals with the
ApoE E4 allele (Petot et al. 2003). When plasma cholesterol
levels are raised, individuals with the ApoE E4 allele are
most responsive to a low-calorie diet, and less responsive to
statin therapy than E2 allele carriers (Gerdes et al. 2000).
While moderate alcohol intake appears to have a beneficial
effect in relation to CVD risk and cognitive decline it may
not be the case in ApoE E4 allele carriers. Anttila et al.
(2004) have shown that the risk of dementia increases with
increasing alcohol consumption only in those individuals
carrying the ApoE E4 allele. A cross-sectional study per-
formed in 685 AD patients from three different ethnic
groups confirmed the deleterious effect of heavy smoking
(one or more packs per day) and alcohol consumption (more
than 2 drinks per day) on cognitive function. Detection of
the ApoE E4 allele, a history of heavy smoking or a history
of heavy drinking was each associated with a 2–3 years
earlier onset of AD. In patients with all three risk factors
AD was diagnosed on average 10 years earlier than in those
with none of the risk factors (Harwood et al. 2010).
According to Seshadri et al. (1995), the lifetime risk of
developing AD is approximately 15% for persons with no
family history and increases to approximately 30% in car-
riers with at least one ApoE E4 allele, compared with less
than 10% for those without the E4 allele. In a more recent
study it was reported that by the age of 85 years, the lifetime
risk of AD without reference to genetic risk factors is
approximately 11% in males and 14% in females.
However, in the presence of the ApoE E4 allele the risk
increases to 51% in males and 60% in females homozygous
for the ApoE E4 allele. In heterozygous carriers the risk was
23% in males and 30% in females, consistent with semi-
dominant inheritance of a moderately penetrant gene (Genin
et al. 2011). Estimates were globally similar and reached the
highest lifetime risk in some European populations, of up to
68% and 35% for females homozygous or heterozygous for
the ApoE 4 allele, respectively. Stratification of the data by
age groups demonstrated that the ApoE E4 allele is a risk
factor not only for late-onset but for early-onset AD as well.
Folate and homocysteine metabolism
Several studies support a role of one-carbon metabolism in
the development of late-onset Alzheimer’s disease. The
protective effect of omega-3 fatty acids discussed above
may be mediated primarily through the vascular system,
while cognitive benefit from a plasma profile high in anti-
oxidants appears to affect the rate of total brain atrophy
related to an AD type pathology. This includes reduction
of oxidative stress (Bowman et al. 2009; Karuppagounder et
al. 2009) and hyperhomocysteinaemia-induced neurotoxici-
ty (Troen et al. 2008). Since homocysteine accumulation
contributes significantly to the risk of both CVD and AD
(Seshadri et al. 2002; Ravaglia et al. 2005), early detection
of genetically increased requirements for folate and other
vitamin co-factors are essential for optimal enzyme function
and consequently vascular and brain health. Detection of var-
iation in the methylenetetrahydrofolate reductase (MTHFR)
gene was shown to be most important in this context and
provides one of the best examples of gene-diet interaction
(nutrigenetics).
In a study performed by Coppede et al. (2011) the authors
demonstrated a significantly increased frequency of the T-
allele of the MTHFR 677C>T polymorphism and the G-
allele of the MTRR 66A>G polymorphism as well as re-
spective heterozygous and homozygous genoptypes in 378
late-onset AD patients compared with 308 matched controls.
These findings correlated significantly with increased mean
plasma homocysteine levels and decreased serum folate
levels. Detection of an interaction between the studied poly-
morphisms and biochemical biomarkers underlines the im-
portance of a combination approach. It enables evaluation of
the effect of both genetic (e.g. MTHFR mutation) and envi-
ronmental factors (e.g. folate intake, smoking, alcohol) on
accumulation of homocysteine in plasma.
Decreased MTHFR activity due to genetic variation is of
special concern in individuals with high alcohol intake since
this may lead to impaired folate status due to malabsorption,
increased excretion, or abnormal folate metabolism (Halsted
et al. 2002). The negative effects of low intake of the
methyl-related nutrients with high intakes of alcohol are
additive, therefore changes in overall dietary patterns are
recommended to ensure the consumption of a protective
high methyl diet. This is essential not only to reduce CVD
risk but also to preserve cognitive function (Ravaglia et al.
2005).
A meta-analysis performed in 3299 AD patients and
4363 controls has shown that the MTHFR T-allele increases
the risk for AD in the general population, particularly in
Asian populations (Hua et al. 2011). These findings are in
accordance with the meta-analysis performed a year earlier
including 19 case-control studies (Zhang et al. 2010). The
frequency of the MTHFR T-allele was found to be signifi-
cantly associated with susceptibility to AD in all subjects. In
a subgroup analysis of individuals without the ApoE E4
allele, the association of the MTHFR 677T-allele with
AD susceptibility was confirmed in Asians but not in
Caucasians. The MTHFR T-allele and mainly the TT
genotype, was found to increase the risk of VaD in Asians
(Liu et al. 2010a). Population difference may be explained by
the fact that genetic influences on homocysteine levels or
disease risk would only be detectable in populations with
low folate status.
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Food fortification and folic acid supplementation repre-
sent confounding factors that need to be taken into account
in research studies and clinical trials (Holmes et al. 2011). In
a study performed by Shmeleva et al. (2003) in North
Western Russia where the population has limited access to
multivitamins and no food fortification, homozygosity for
the T-allele of the MTHFR 677>T polymorphism was
detected in all persons with homocysteine levels above
30 μm/l. Amongst carriers with the T allele, thrombotic risk
increased 1.9-fold in patients with arterial thrombosis, 1.7-
fold for venous thrombosis and 2.5 fold for both conditions.
These findings are in accordance with the risk for recurrent
venous thrombosis ascribed to the MTHFR genotype by
Keijzer et al. (2002). These authors reported a relative risk
of between 1.4 and 1.6 in the presence of the T-allele and a
combined risk of 18.7 if detected in the presence of the
factor V Leiden mutation, the most common genetic risk
factor for venous thrombosis. Detection of one or more
genetic risk factors causing abnormal blood clotting in
patients with venous thrombosis represents another prevent-
able CVD subtype identifiable with the multigene assay
referred to in Table 1.
Nutritional requirements differ according to the MTHFR
genotype (Moriyama et al. 2002; Herrmann et al. 2003).
Individuals with genetic variations in the MTHFR gene may
require increased amounts of folate above the recommended
daily allowance (RDA) of 400 μg per day, together with
adequate amounts of vitamins B6 and B12. Determination
of homocysteine levels and genetic testing performed in
conjunction with dietary assessment may therefore serve as
useful parameters for improvement of a person’s diet. It is
not sufficient to perform a biochemical test of plasma homo-
cysteine levels alone, as these levels fluctuate as a conse-
quence of environmental changes (e.g. medication, diet,
alcohol intake). A specific DNA test, on the other hand, is
performed only once in a lifetime (1) to determine the
underlying cause of high homocysteine levels and/or (2) to
determine the appropriateness of food supplementation and
dosages. As elevated plasma homocysteine is a marker of
folate and vitamin B12 deficiency that may lead to many
common disorders including CVD and AD, it is important
to focus on the prevention of hyperhomocysteinaemia.
Before wide implementation of genetic testing could be
promoted in the context of CVD, however, consideration
had to be given to the uncertainty of whether the association
between elevated serum homocysteine levels and CVD is
indeed causal. The meta-analysis performed by Wald et al.
(2002) provided strong evidence for causality, because both
genetic and prospective studies (that do not share the same
potential sources of error) yielded highly significant results.
Lowering of homocysteine concentrations by 3 mmol/l by
increasing folic acid intake was predicted to reduce the risk
of ischaemic heart disease by 16%, deep vein thrombosis by
25%, and stroke by 24% (Wald et al. 2002). In a meta-
analysis performed by Klerk et al. (2002), individuals with
two copies of the most extensively studied 677C>T muta-
tion (T-allele) were found to have a 16% higher risk of CHD
compared with individuals homozygous for the common
allele. The increased risk of stroke associated with the T-
allele was furthermore confirmed in a meta-analysis involv-
ing 14870 individuals (Cronin et al. 2005). The benefits of
folic acid supplementation are explained largely by favour-
able endothelial function outcomes after lowering homocys-
teine levels, as assessed by flow-mediated vasodilation or
haemostatic markers (Brown and Hu 2001). Genetic testing
may identify individuals at risk of homocysteine accumula-
tion before damage occurs to DNA, arteries and the brain.
Vascular risk factors such as high homocysteine levels
may modify the neurodegenerative process in patients with
mild cognitive impairment (MCI) at increased risk of VaD
and AD. The MTHFR 677 TT genotype was shown to
promote plasma homocysteine increase which in turn may
favour intima-media thickening in patients with cognitive
impairment (Gorgone et al. 2009). In a one year follow-up
study of 55 patients with mild cognitive impairment and 44
controls matched for age, gender and education, vascular
risk factors were found significantly more often in the MCI
group, including the ApoE E4 allele (p00.018), hyperho-
mocysteinaemia (p-0.012) and folate deficiency (p00.023)
(Siuda et al. 2009). However, whether these findings trans-
late into significant changes at the clinical level is uncertain
as only age and hypertension influenced the progression
from MCI to dementia within one year of this prospective
observation. The influence of the ApoE E4 allele on the risk
of AD was independent of MTHFR mutation status and
homocysteine levels (Styczyńska et al. 2008).
Iron metabolism
The importance of iron metabolism extends beyond the field
of nutrition, representing a key factor in pathology, cardiology,
oncology, neurological and infectious diseases. Brain iron
increases with age and is elevated in AD and several other
neurodegenerative diseases, correlating with earlier age of
onset in men. In a recent study performed by Bartzokis et al.
(2011) it was shown that higher accumulation of iron in
vulnerable gray matter regions may represent a risk factor
for accelerated cognitive decline. Variation in numerous genes
may interact with each other and the diet to determine iron
levels in serum and the brain and age of onset of AD (van
Rensburg et al. 2000; Sampietro et al. 2001). Bartzokis et al.
(2010) reported that highly prevalent genetic variants in iron
metabolism genes can influence brain iron levels in men.
Identification of the mechanisms underlying brain iron
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accumulation may lead to novel ways to offer neuroprotection
for age-related neurodegenerative diseases.
More than 10 years ago we demonstrated an earlier age of
onset in South African patients with AD with both the ApoE
E4 allele and the transferrin (TF) C2 polymorphism (Van
Rensburg et al. 2000). The significance of TF C2 in AD has
subsequently been confirmed in several studies, including
the Epistasis Project conducted by Lehmann et al. (2012).
The previously reported interaction between the C282Y
mutation in the haemochromatosis (HFE) gene and TF C2
in Northern Europeans was confirmed in a comparative
study of 1757 patients with AD and 6295 controls.
Homozygosity for both the HFE H63D mutation and anoth-
er variation in the TF gene were also found to be signifi-
cantly associated with iron loading. Based on these findings,
it was concluded that treatment for iron overload may thus
be protective in some cases.
The TF C2 variant has an increased allele frequency in
AD patients compared to controls in some populations (Van
Rensburg et al. 1993; Zambenedetti et al. 2003), but not in
others, such as in a French population of the Bordeaux
region (Rondeau et al. 2006). Since TF C2 is associated
with diseases attributed to oxidative damage, it may be
hypothesised that diet may have an effect on the expression
of the TF C2 variant. In an environment such as Bordeaux,
where a predominantly Mediterranean diet and red wine rich
in anti-oxidants are consumed regularly, the deleterious
effects of TF C2 variant may be neutralised (Van Rensburg
et al. 2010).
The deleterious effects of mutations in the HFE gene are
usually ascribed to their role in cellular iron overload.
However, in the case of mutation H63D found to be over-
represented in AD patients, the mutant protein is associated
with prolonged stress of the endoplasmic reticulum and
chronically increased neuronal vulnerability as demonstrat-
ed in an inducible expression cell model (Liu et al. 2011).
While the C282Y mutation is more commonly associated
with hereditary haemochromatosis (considered a prevent-
able cause of heart disease and other equally important
clinical conditions due to potential organ damage), H63D
has received more attention for its role in neurodegenerative
diseases. HFE gene variants are considered important in this
context due to the association of the HFE H63D mutant
protein with iron dyshomeostasis, increased oxidative stress,
tau phosphorylation, glutamate release and inflammation at
the cellular level (Nandar and Connor 2011).
The importance of assessing genetic risk factors together
with relevant blood biochemistry parameters was demon-
strated in the study of Giambattistelli et al. (2011). These
authors explored the interconnectedness of genetic variation
in the HFE (H63D and C282Y) and TF (C2) genes with serum
markers of iron status, including iron, ferritin, TF and TF-
saturation, as well as liver function (albumin, transaminases)
and prothrombin time in 160 AD patients and 79 healthy
controls. The results of the liver function tests indicated dis-
tress of the liver. TF concentration was lower and ferritin
higher in AD patients. Statistical analyses revealed that a
one-unit TF serum decrease increases the probability of AD
by 80%,while a one-unit increase of AST/ALT ratio generates
a 4-fold probability increase. The HFE H63D mutation was
associated with higher levels of iron and lower levels of TF.
These results suggest that the presence of HFE mutations and
iron abnormalities may increase the probability of developing
AD when accompanied by distress of the liver.
In contrast to the above studies providing strong evidence
that the HFE H63D mutation is a risk factor for AD when
evaluated in conjunction with other relevant biomarkers to
assess cumulative effects, a meta-analysis of 22 studies
performed in 4365 cases and 8652 controls implicated it as
a protective factor (Lin et al. 2011). The previously reported
association of HFE C282Y with increased risk of AD could
also not be confirmed.
We believe that the only way to overcome the limitations
of low-penetrance genetics is to combine DNA tests with
relevant pathology or blood biochemistry such as cholester-
ol, serum iron status, oxidative stress, inflammatory markers
and liver function tests as appropriate. For example, bio-
chemical abnormalities associated with low penetrance
mutations in the Apo E (cholesterol) and HFE (ferritin,
transferrin saturation) genes, respectively, are usually not
detectable early in life. As the pathology may develop over
a long period of time, preventative measures can be imple-
mented based on this knowledge when a genetic risk factor
is identified in the presence of known environmental trig-
gers that could be eliminated or targeted during intervention.
Application of the PSGT approach has been discussed pre-
viously in the context of iron metabolism (Kotze et al.
2009). Hereditary haemochromatosis (HH) provides an ex-
cellent example of a complex disease that is best addressed
by the PSGT approach, which requires that (1) genetic
testing is performed within a specific pathology/biochemical
and clinical profile that also defines the test selection crite-
ria, (2) the patient report contains both the biochemical and
genetic test results for clinical application in the context of
relevant documented environmental factors, and (3) gene
expression and monitoring of response to treatment are
assessed through the accompanying pathology and genetic
test parameters. This approach has proved valuable to dis-
tinguish patients with HH from those with the dysmetabolic
or insulin-resistance iron overload disorder frequently ob-
served in patients with non-alcoholic fatty liver disease
(NAFLD). NAFLD is the hepatic manifestation of MetS
and is considered an independent risk factor for CVD.
Ghareeb et al. (2011) have demonstrated that NAFLD may
induce insulin resistance and metabolic disorders associated
with age-associated neurodegenerative diseases such as AD.
Metab Brain Dis (2012) 27:255–266 261
The identification of the spectrum of risk factors under-
lying iron overload provides a major healthcare opportunity
to reduce the burden of dementia, heart disease, cancer,
diabetes, arthritis, infertility and many other complications
of organ damage in the general population.
Body mass index
Recently, variation in the fat mass and obesity-associated
(FTO) gene was identified as the most significant genetic risk
factor for susceptibility of polygenic obesity. With more than
300 million obese persons worldwide it is crucial to under-
stand the clinical implications of genetic variation in the FTO
gene (Ho et al. 2010). A functional SNP in intron 1 of the FTO
gene (rs9939609) (Berulava and Horsthemke 2010) occurs in
nearly 50% of the general population and is associated with an
approximately 1.2 kg higher weight, on average, in adults and
an approximately 1 cm greater waist circumference (Liu et al.
2010a, b). The effect of the FTO gene to increase the risk of
obesity and diabetes may be mediated through epigenetic
changes (Almén et al. 2012). Both a high BMI and diabetes
linked to the FTO gene are vascular risk factors implicated in
the development of VaD and AD.
Much interest is currently focused on the possibility that the
FTO gene affects brain function and structure as a high BMI
correlates with frontal, temporal and subcortical atrophy
(Bertram and Heekeren 2010). FTO is highly expressed in the
human brain and primarily affects frontal lobe-dependent cogni-
tive processes (Benedict et al. 2011). This was shown in a study
of verbal fluency performance in 355 elderly men who had no
clinically apparent cognitive impairment at the age of 82 years.
Obese and overweight but not normal weight individuals with
the FTOA-allele showed a lower performance on verbal fluency
than homozygotes for the T-allele (Benedict et al. 2011).
Generation of 3D maps of regional brain volume revealed
a pattern of systematic brain volume deficits in subjects with
FTO obesity-associated risk alleles when compared with
non-carriers (Ho et al. 2010). The average brain volume
difference for the frontal lobes and the occipital lobes were
approximately 8% and 12%, respectively, with the greatest
effects in individuals with high BMI’s. These brain differ-
ences were not attributable to the effect of cholesterol,
hypertension or the volume of white matter hyperintensities.
In a nine-year prospective follow-up study exploring the
impact of FTO on AD and dementia risk in 1003 persons
without dementia, individuals with the FTO AA genotype
showed a higher risk of cognitive decline after adjustment
for age, gender, education, physical activity, BMI, diabetes,
CVD and ApoE genotype (Keller et al. 2011). Co-
inheritance of both the FTO AA genotype and Apo E4 allele
was associated with a significantly increased risk of demen-
tia, and particularly AD. The FTO gene effect acts mostly
through interaction with the Apo E4 allele, independently of
physical activity, BMI, diabetes and CVD. These results are
in accordance with an association between FTO and reduced
brain volume reported by Ho et al. (2010).
In a study performed by Moleres et al. (2011) the strong
influence of dietary fatty acid distribution on the effect of
the rs9939609 polymorphism in the FTO gene on obesity
risk was clearly demonstrated from childhood. Genotyping
of rs9939609 in 354 Spanish children and adolescents aged
6–18 years (49% males), showed a statistically significant
interaction between the consumption of saturated fatty acids
(SFA) (percentage of total energy) in relation to polyunsat-
urated fatty acid (PUFA) intake and obesity risk linked to
the rs9939609 SNP of the FTO gene. Risk allele carriers
consuming more than 12.6% SFA (of total energy) had an
increased obesity risk compared with TT carriers. In a sim-
ilar way, A allele carriers with an intake ratio lower than
0.43 PUFA:SFA presented a higher obesity risk than TT
subjects. These findings emphasise the importance of early
detection of a genetic predisposition for obesity so that
preventative measures can be implemented to prevent cu-
mulative risk that may lead to CVD and/or AD.
Genetic testing for optimised treatment
The above-mentioned information highlights the importance
of early identification of CVD risk factors and timely inter-
vention before cognitive decline becomes apparent. While
current practice is generally to address symptoms as they
occur, several studies point out the importance of treating
CVD risk factors as early as midlife (Solomon et al. 2009).
According to the World Health Organisation eight risk
factors account for over 75% of CVD, namely hypertension,
high body mass index, high cholesterol, high blood glucose,
low fruit and vegetable intake, high alcohol consumption
and physical inactivity. In a study performed in more than
800 Caucasians (Szolnoki et al. 2003) it was shown that the
presence of the Apo E4 allele worsened the unfavourable
effects of hypertension, diabetes mellitus, smoking, or
drinking on the incidence of ischaemic stroke. Synergistic
effects were also found between the MTHFR 677TT geno-
type and alcohol consumption or smoking, while detection
of a genetic predisposition for venous thrombosis (e.g. fac-
tor V Leiden mutation) in combination with hypertension
and diabetes mellitus increased the risk of ischaemic stroke.
A study performed by Volzke et al. (2005) confirmed the
increased risk of atherosclerosis with rising serum LDL-
cholesterol concentrations in carriers of the factor V
Leiden mutation. In a study performed in 12 239 women
between the ages of 51 to 69 years, Roest et al. (1999) demon-
strated that inherited variation in iron metabolism (HFE gene)
is involved in cardiovascular death in postmenopausal women,
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especially in women already carrying classic risk factors such
as hypertension and smoking (Roest et al. 1999). These find-
ings confirm the importance of early detection of a genetic
contribution to clinical risk factors for disease prevention.
Therapeutic responses may also be genotype specific and
this could contribute to the apparent inability of presently
available drugs to alter the course of AD for some patients.
Approximately 15% of AD cases with adverse response to
treatment are associated with a defective CYP2D6 gene
which can be assessed genetically (Cacabelos 2003).
Pharmacogenetic response may be influenced not only by this
gene involved in drug metabolism, but also genes involved in
the pathogenesis of both CVD andAD. Patients with the ApoE
E4 allele appear to be the worst responders to both cholesterol-
lowering statin treatment and various drugs prescribed to AD
patients (Cacabelos 2008). This author suggested that the
presence of the ApoE-44 genotype could convert CYP2D6
extensive metabolisers into poor metabolisers. If confirmed in
future studies, gene-gene interaction between the Apo E and
CYP2D6 genes may have important clinical implications for
treatment of a wide range of chronic disorders.
The key to disease prevention therefore lies in a better
understanding of gene-environment interactions underlying
CVD and AD and effective intervention based on this knowl-
edge (Fig. 1) (Kotze et al 2006). Genetic testing enables the
dissection of complex conditions into treatable subtypes; for
example to distinguish between FH patients requiring long-
term drug treatment and those with the ApoE E4 allele who
respond well to specific dietary and lifestyle changes without
the use of medication.
Conclusions
Genetic testing of CVD risk factors has the potential to
translate into improved health outcomes in patients with
cognitive impairment and their at-risk family members.
Based on the knowledge that assessment and treatment of
CVD risk factors in middle age may reduce the risk of heart
disease and dementia in old age (Kotze et al. 2006), a
comprehensive PSGT approach was developed. Since the
deleterious effects of several genetic risk factors shared
between CVD and AD are mediated through diet and life-
style factors, identification of a genetic predisposition high-
lights the importance of smoking cessation where relevant
and a healthy diet with regular intake of foods that offer
neuroprotection. In contrast to severe CVD subtypes such as
FH that requires aggressive treatment, simple lifestyle
changes can delay the onset and severity of dementia
(Potocnik et al. 2005).
Contrary to previous belief, the identification of AD
genetic risk factors that may be triggered by environmental
factors does not result in increased worrying and depression
(Romero et al. 2005). Genetic testing for multiple CVD risk
factors in conjunction with nutrition and cognitive assess-
ment may empower patients to take the necessary steps to
improve their health. The remaining gaps in our knowledge
Hudson et al. (2012) necessitate a transdisciplinary PSGT
approach linked to ongoing health outcome studies.
Educational campaigns that highlight the link between
CVD risk factors and AD may help reduce the impact of
both conditions.
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Fig. 1 Co-inheritance of multiple genetic risk factors in the presence
of environmental triggers has a significant impact on the development
of clinical conditions associated with the development of cardiovascu-
lar disease (CVD) and/or Alzheimer’s disease (AD). Environmental
factors that may be either harmful or beneficial (right column) in the
context of their direct effect on genetic factors underlying the high-risk
clinical conditions highlighted in the circles on the outside, can poten-
tially be manipulated to prevent the conversion of genetic risk factors
into disease (Reproduced with permission from Kotze et al. 2006)
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